1049809-94-0Relevant articles and documents
Pyrazole-based arylalkyne Cathepsin S inhibitors. Part III: Modification of P4 region
Wiener, John J.M.,Wickboldt, Alvah Tyson,Nguyen, Steven,Sun, Siquan,Rynberg, Raymond,Rizzolio, Michele,Karlsson, Lars,Edwards, James P.,Grice, Cheryl A.
, p. 1070 - 1074 (2013/03/13)
Novel classes of tetrahydropyrido-pyrazole thioether amines and arylalkynes that display potency against human Cathepsin S have been previously reported. Here, key pharmacophoric elements of these two classes are merged, and SAR investigations of the P4 region are described, in conjunction with re-optimization of the P5 and P1/P1′/P3 regions. Identification of meta-substituted arylalkynes with good potency and improved solubility is described.
PROCESSES FOR THE PREPARATION OF CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S
-
Page/Page column 21, (2009/10/09)
Method of making carbon-linked tetrahydro-pyrazolo-pyridine compounds of the following Formula (I) and pharmaceutically acceptable salts thereof: comprising reacting a compound of formula (IX): with a compound of formula (X): to form a compound of Formula
CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S
-
Page/Page column 105, (2008/12/08)
Carbon-linked tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.